Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients

Pathology

Volumn 45, Issue 6, 2013, Pages 574-580

  Noh, Sang Jae ^a   Kang, Myoung Jae ^a   Kim, Kyoung Min ^a   Bae, Jun Sang ^a   Park, Ho Sung ^a   Moon, Woo Sung ^a   Chung, Myoung Ja ^a   Lee, Ho ^a   Lee, Dong Geun ^a   Jang, Kyu Yun ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Acetylation; Androgen receptor; DBC1; P53; Renal cell carcinoma; SIRT1

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; DBC1 PROTEIN, HUMAN; PROTEIN P53; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ACETYLATION; ADULT; AGED; ARTICLE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; VERY ELDERLY;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SIRTUIN 1; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84887916723     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283652c7a     Document Type: Article

References (45)

1. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
2. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48.
3. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009; 58: 344-51.
4. Jang KY, Noh SJ, Lehwald N, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012; 7: e45119.
5. Menssen A, Hydbring P, Kapelle K, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase forma positive feedback loop. Proc Natl Acad Sci USA 2012; 109: E187-96.
6. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
7. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627-38.
8. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437-48.
9. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
10. Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32: 1523-31.
11. Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009; 15: 4453-9.
12. Lee H, Kim KR, Noh SJ, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011; 42: 204-13.
13. Lovaas JD, Zhu L, Chiao CY, et al. SIRT1 enhances matrix metalloproteinase- 2 expression and tumor cell invasion in prostate cancer cells. Prostate 2013; 73: 522-30.
14. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-6.
15. Hamaguchi M, Meth JL, von Klitzing C, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 2002; 99: 13647-52.
16. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008; 451: 583-6.
17. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64: 4040- 8.
18. Lenburg ME, Liou LS, Gerry NP, et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003; 3: 31.
19. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus- negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19.
20. Radvanyi L, Singh-Sandhu D, Gallichan S, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 2005; 102: 11005-10.
21. Kim SH, Kim JH, Yu EJ, et al. The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis. Histol Histopathol 2012; 27: 49-58.
22. Hiraike H,Wada-Hiraike O, Nakagawa S, et al. Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 2010; 102: 1061-7.
23. Li Z, Chen L, Kabra N, et al. Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 2009; 284: 10361-6.
24. Fu J, Jiang J, Li J, et al. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem 2009; 284: 6832-40.
25. Ma WL, Hsu CL, Wu MH, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008; 135: 947-55; 55 e1-5.
26. Sheach LA, Adeney EM, Kucukmetin A, et al. Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 2009; 101: 498-503.
27. Li R, Wheeler T, Dai H, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28: 928-34.
28. Kominea A, Konstantinopoulos PA, Kapranos N, et al. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol 2004; 130: 253-8.
29. Zhang X, He L, Lu Y, et al. Androgen receptor in primary hepatocellular carcinoma and its clinical significance. Chin Med J (Engl) 1998; 111: 1083-6.
30. Langner C, Ratschek M, Rehak P, et al. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 2004; 171: 611-4.
31. Eble JL, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs: WHO Classification of Tumours. Lyon: World Health Organization, 2004.
32. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63.
33. Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer, 2010.
34. Noon AP, Vlatkovic N, Polanski R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 2010; 116: 780-90.
35. Strano S, Dell'Orso S, Di Agostino S, et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007; 26: 2212-9.
36. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3: e2020.
37. Jang KY, Kim KS, Hwang SH, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41: 366-71.
38. Trauernicht AM, Kim SJ, Kim NH, et al. Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol 2007; 21: 1526-36.
39. Segawa N, Mori I, Utsunomiya H, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-9.
40. Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 2011; 108: 24-30.
41. Cardillo MR, Petrangeli E, Aliotta N, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998; 17: 231-7.
42. Brown DF, Dababo MA, Hladik CL, et al. Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas. Mod Pathol 1998; 11: 55-9.
43. Elattar A, Warburton KG, Mukhopadhyay A, et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 2012; 124: 142-7.
44. Shyr CR, Chen CC, Hsieh TF, et al. The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine 2013; 43: 191-9.
45. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004; 64: 383-8.